Abstracts tagged "COVID-19"

Abstract Number: 0566 • ACR Convergence 2022
SARS-CoV-2-Specific T Cell Responses in Multisystem Inflammatory Syndrome in Children
Ki Pui Lam¹, Marcos H. Chinas², Amélie M. Julé², Maria Taylor³, Mary Beth F. Son¹, Janet Chou², Jane W. Newburger⁴, Adrienne G. Randolph⁵, Maria Gutierrez-Arcelus² and lauren henderson¹, ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ³Division of Immunology, Boston Children's Hospital, Brighton, MA, ⁴Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ⁵Division of Critical Care Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) develops about a month after SARS-CoV-2 infection and this delayed presentation suggests a role for the adaptive immune…
Abstract Number: 0759 • ACR Convergence 2022
Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRD) on Immunomodulatory Therapies (IMT): An Updated Cohort Study
Gordon Lam¹, Andrew Laster¹, Heather Gladue¹, Ahmad Kashif¹, Erin Siceloff², Victoria Lackey¹, Cheryl Robertson¹, Ashley Toci¹, Maggie McCarter³ and Leonard Calabrese⁴, ¹Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²Arthritis and Osteoporosis Consultants of the Carolinas, Stallings, NC, ³University of South Carolina, Columbia, SC, ⁴Cleveland Clinic, Cleveland, OH
Background/Purpose: AIIRD patients may have a blunted immune response to the COVID-19 vaccines, but this is uncertain as these individuals were not included in clinical…
Abstract Number: 0789 • ACR Convergence 2022
The Persistence of Anti-Spike Antibodies Following Two SARS-CoV-2 Vaccine Doses in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy Compared to Healthy Controls: A Prospective Cohort Study
Ingrid Egeland Christensen¹, Ingrid Jyssum¹, Anne Therese Tveter¹, Joe Sexton¹, Siri Mjaaland², Grete Birkeland Kro³, Tore K. Kvien¹, David Warren³, Jørgen Jahnsen⁴, Ludvig A. Munthe³, Espen Haavardsholm¹, Gunnveig Grødeland³, Kristin Kaasen Jørgensen⁴, Silje Watterdal Syversen¹, Guro Løvik Goll¹ and Sella Aarrestad Provan¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Norwegian Institute of Public Health, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Akershus University Hospital, Oslo, Norway
Background/Purpose: The durability of vaccine-induced humoral immunity against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy is not well characterized. The aim…
Abstract Number: 0882 • ACR Convergence 2022
Gender Differences in Rheumatology Authorship: A Bibliometric Analysis of High Impact Rheumatology Journals from 2019-2021
Neha Chaurasia¹, Priyanka Iyer¹ and Melody Esmaeili-Ghahfarokhi², ¹University of California Irvine, Orange, CA, ²University of California Irvine, Orange
Background/Purpose: Recent data suggests the COVID-19 pandemic disproportionately affected productivity of women in the workforce. This bibliometric analysis examines gender differences in authorship of manuscripts…
Abstract Number: 1213 • ACR Convergence 2022
Trends of Opioid Prescriptions and Impact of the COVID-19 Pandemic Among Patients with Musculoskeletal Diseases Between 2006-2021
Joyce (Yun-Ting) Huang¹, David Jenkins², Belay Birlie Yimer¹, Jose Benitez-Aurioles², Niels Peek², Mark Lunt¹, Will Dixon³ and Meghna Jani¹, ¹Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, United Kingdom, ²Division of Informatics, The University of Manchester, Manchester, United Kingdom, ³The University of Manchester, Manchester, United Kingdom
Background/Purpose: Opioid prescribing has contributed to a North American epidemic with increasing trends in several European countries. Rheumatic and musculoskeletal diseases (RMDs) are one of…
Abstract Number: 1756 • ACR Convergence 2022
Adverse Events in Patients with Inflammatory Joint Diseases: Results from the EULAR Coronavirus Vaccine (COVAX) Physician-reported Registry
Ana Lúcia Martins Fernandes¹, Jose A Gomez-Puerta², Juan Camilo Sarmiento-Monroy², Saskia Lawson-Tovey³, Kimme Hyrich⁴, Laure Gossec⁵, Loreto Carmona⁶, Anja Strangfeld⁷, Elsa Mateus⁸, Ana Maria Rodrigues⁹, Eric Hachulla¹⁰, Marta Mosca¹¹, Patrick Durez¹², Bernd Raffeiner¹³, Nicolas Roux¹⁴, Viellard Eric¹⁵, Olivier Brocq¹⁶, Julija Zepa¹⁷, Inita Bulina¹⁸, Eva Strakova¹⁹, Vanda Mlynarikova²⁰, Emoke Šteňová²¹, Martin Soubrier²², Xavier Mariette²³ and Pedro Machado²⁴, ¹Centro Hospitalar Universitário do Algarve, Faro, Portugal, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, the University of Manchester, Manchester, UK AND National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴The University of Manchester, Manchester, United Kingdom, ⁵Sorbonne Université, Paris, France, ⁶Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁷Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁸EULAR, Lisboa, Portugal, ⁹Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal, ¹⁰University of Lille, LILLE, France, ¹¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹²Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ¹³Department of Rheumatology, Central Hospital of Bolzano, Bolzano, Italy, ¹⁴Service de Rhumatologie, Hôpital Robert Schuman, Metz, France, ¹⁵Private practice, St. Malo, France, ¹⁶Rheumatology- CH Princesse Grace, Monaco, Monaco, ¹⁷Riga Stradins University, Latvia, Pauls Stradins Clinical University Hospital, Centre of Rheumatology, Riga, Latvia, Riga, Latvia, ¹⁸Center of Rheumatology, Paul Stradins Clinical University hospital, Riga, Latvia, Riga, Latvia, ¹⁹Department of Internal Medicine, Faculty Hospital Prešov, Presov, Slovakia, ²⁰National Institute of Rheumatic Diseases, Piešťany, Slovakia, ²¹University Hospital, Bratislava, Slovakia, ²²Gabriel-Montpied Hospital, Clermont-Ferrand, France, ²³Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ²⁴University College London, London, United Kingdom
Background/Purpose: Patients with inflammatory/autoimmune rheumatic and musculoskeletal diseases (I-RMDs) were excluded from SARS-CoV-2 vaccination development programs. Therefore, concerns regarding the safety and effectiveness of SARS-CoV-2…
Abstract Number: 1930 • ACR Convergence 2022
Assessing the Number of Children Evaluated for Recurrent Fevers During the COVID-19 Pandemic in North America
Leanne Mansfield¹, Sivia Lapidus², Matthew Hollander³, Julie Cherian⁴, Marinka Twilt⁵, Maryam Piram⁶, Lakshmi Moorthy⁷, Brian Nolan⁸, Geraldina Lionetti⁹, Eveline Wu¹⁰, Heather Tory¹¹, Elizabeth Kessler¹², Cassyanne Aguiar¹³, Sirada Panupattanapong¹⁴, Shoghik Akoghlanian¹⁵, Felice Adler-Shohet¹⁶, Melissa Oliver¹⁷, Smriti Mohan¹⁸, Patricia DeLaMora¹⁹, Karen Durrant²⁰, Theresa Wampler Muskardin²¹, Samira Nazzar²², Mariana Correia Marques²³, Matthew Basiaga²⁴, Tiphanie vogel²⁵, Jamie Lai²⁵, Kathryn Edwards²⁶, Kathryn Garguilo²⁶, Sheila Nolan¹⁹, Emily Sheboy Scarcello²⁷, Gabrielle Alonzi²⁸, Ann Szymanski²⁹, Joyce Hui-Yuen³⁰, karen onel³¹, Fatma Dedeoglu³², Maria Gutierrez³³, Grant Schulert³⁴ and CARRA PFAPA/Autoinflammatory Working Group N/A³⁵, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Joseph M. Sanzari Children's Hospital Hackensack University Medical Center, Montclair, NJ, ³University of Vermont Medical Center Children's Hospital, Burlington, VT, ⁴Renaissance School of Medicine at Stony Brook University, Stony Brook Children’s Hospital, Stony Brook, NY, ⁵Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁶CHU Sainte Justine, University of Montreal, Montréal, QC, Canada, ⁷Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ⁸Ann & Robert H. Lurie Children's Hospital, Chicago, IL, ⁹UCSF Benioff Children's Hospitals, Oakland, CA, ¹⁰University of North Carolina, Chapel Hill, NC, ¹¹Connecticut Children's Medical Center and University of Connecticut School of Medicine, S Glastonbury, CT, ¹²Spectrum Health Helen DeVos Children's Hospital, Michigan State University, Grand Rapids, MI, ¹³Children’s Hospital of The King’s Daughters / Eastern Virginia Medical School, Norfolk, VA, ¹⁴Cleveland Clinic Children's, Cleveland, OH, ¹⁵Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ¹⁶University of California, Irvine and Children’s Hospital of Orange County, Orange, CA, ¹⁷Indiana University School of Medicine, Indianapolis, IN, ¹⁸University of Michigan Medical School, Ann Arbor, MI, ¹⁹Boston Children's Health Physicians, New York Medical College, Valhalla, NY, ²⁰Autoinflammatory Alliance, San Francisco, CA, ²¹Colton Center for Autoimmunity, NYU School of Medicine, New York, NY, ²²University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, ²³Children's National Health System/National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²⁴Mayo Clinic, Inver Grove Heights, MN, ²⁵Baylor College of Medicine, Houston, TX, ²⁶Vanderbilt University Medical Center, Nashville, TN, ²⁷Boston Children's Health Physicians, Valhalla, NY, ²⁸Boston Children's Hospital, Boston, MA, ²⁹Johns Hopkins All Children’s Hospital, St. Petersburg, FL, ³⁰Cohen Children’s Medical Center, Hofstra-Northwell School of Medicine, Feinstein Institutes for Medical Research, Queens, NY, ³¹Hospital for Special Surgery, New York, NY, ³²Division of Immunology, Boston Children's Hospital, Boston, MA, ³³Johns Hopkins University School of Medicine, Baltimore, MD, ³⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³⁵CARRA, Washington, DC
Background/Purpose: The impact of the COVID-19 pandemic on the number of pediatric patients evaluated in North America for recurrent fevers and autoinflammatory diseases is unknown;…
Abstract Number: 2196 • ACR Convergence 2022
Risk Factors for Severe COVID-19 Outcomes: A Study of Immune-mediated Inflammatory Diseases, Immunomodulatory Medications, Vaccination Status, and Comorbidities in a Large US Healthcare System
Philip J Mease¹, Qi Wei², Michael Chiorean¹, Lulu Iles-Shih¹, Wanessa Matos², Andrew Baumgartner², Sevda Molani², Yeon Mi Hwang², Basazin Belhu² and Jennifer Hadlock², ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Institute for Systems Biology, Seattle, WA
Background/Purpose: Reported infection rates and severe outcomes of COVID-19 in patients with immune-mediated inflammatory diseases (IMIDs) and their therapy, have varied depending on the nature…
Abstract Number: 0186 • ACR Convergence 2022
Evaluating the Effectiveness & Impact of an In-Person Peer Support Group That Transitioned to a Virtual Platform During the COVID-19 Pandemic
Giselle Rodriguez¹, Priscilla Calvache¹, Lillian Mendez¹, Kimberly Cabrera¹, Roberta Horton¹, Lisa Imundo² and Jillian Rose-Smith¹, ¹Hospital for Special Surgery, New York, NY, ²New York Presbyterian Hospital - Columbia Campus, New York, NY
Background/Purpose: Studies have demonstrated the benefits of online peer support forums in meeting the mental health, disease self-management & coping needs of people living with…
Abstract Number: 0685 • ACR Convergence 2022
The Association of Antiphospholipid Antibodies with Previous SARS-CoV-2 Infection Among Elective Knee Replacement Patients
Lisa Mandl, Medha Barbhaiya, Robyn Lipschultz, Benjamin Swett, Myriam Lin, Agnes Cororaton, Dongmei Sun, Kethy Jules-elysee, Doruk Erkan and Friedrich Boettner, Hospital for Special Surgery, New York, NY
Background/Purpose: Acute SARS-CoV-2 infection has been associated with antiphospholipid antibodies (aPL), though it is unclear if aPL contribute to the hypercoagulability seen with COVID19, or…
Abstract Number: 0762 • ACR Convergence 2022
Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders
Christian Ammitzboell¹, marianne Kragh thomsen², Jakob Bøgn Andersen¹, Jens Magnus Berth Jensen³, marie-Louise From Hermansen¹, anders Dahl Johannsen¹, Mads Lamm Larsen¹, Clara Elbæl Mistegaard¹, Susan Mikkelsen³, Fruzsina Szabados³, Signe Risbøl Vils¹, Christian Erikstrup³, Ellen-Margrethe Hauge¹ and Anne Troldborg¹, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Treatment with rituximab (RTX) has presented a challenge during the COVID-19 pandemic, as antibody response after primary vaccination are markedly reduced and often undetectable.The primary…
Abstract Number: 0790 • ACR Convergence 2022
Sustainability of Immunogenicity of BNT162b2 Vaccine in Patients with Autoimmune Rheumatic Disease, a Retrospective Comparative Study
Omar Alsaed, Masautso Chaponda, Eman Satti, Hadil Ashour, Muna Almaslamani and Samar Al emadi, Hamad Medical Corporation, Doha, Qatar
Background/Purpose: The sustainability of the immunogenicity of BNT162b2 anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in patients with autoimmune rheumatic diseases (ARDs) receiving immunomodulators…
Abstract Number: 0895 • ACR Convergence 2022
COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Rheumatoid Arthritis
Naveen R¹, Ioannis Parodis², Mrudula Joshi³, Parikshit Sen⁴, Minchul Kim⁵, Vishwesh Agarwal⁶, Sinan Kardes⁷, James B. Lilleker⁸, Hector Chinoy⁹, Oliver Distler¹⁰, Ai Lyn Tan¹¹, Samuel Shinjo¹², Babur Salim¹³, Tamer A Gheita¹⁴, Nelly Ziade¹⁵, Tsvetelina Velikova¹⁶, Tulika Chatterjee⁵, Arvind Nune¹⁷, Marcin Milchert¹⁸, Abraham Edgar Gracia-Ramos¹⁹, Albert Selva O’Callaghan²⁰, Miguel Angel Saavedra Salinas²¹, Lorenzo Cavagna²², Masataka Kuwana²³, Johannes Knitza²⁴, Jessica Day²⁵, Ashima Makol²⁶, John Pauling²⁷, Chris Wincup²⁸, Erick Zamora Tehozol²⁹, Jorge Rojas Serrano³⁰, Ignacio Garcia-De La Torre³¹, Rohit Aggarwal³², Vikas Agarwal¹, Latika Gupta³³, Elena Nikiphorou³⁴ and CoVAD Study Group³⁵, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Karolinska Institutet, Stockholm, Sweden, ³Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ⁴Maulana Azad Medical College, New Delhi, India, ⁵University of Illinois College of Medicine Peoria, Peoria, IL, ⁶Mahatma Gandhi Missions Medical College, Lucknow, India, ⁷Istanbul University, Istanbul, Turkey, ⁸The University of Manchester, Manchester, United Kingdom, ⁹The University of Manchester, Sale, United Kingdom, ¹⁰Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ¹¹University of Leeds, Leeds, United Kingdom, ¹²Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, ¹³Fauji foundation hospital Rawalpindi, Rawalpindi, Pakistan, ¹⁴Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹⁵Saint-Joseph University, Beirut, Lebanon, ¹⁶Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹⁷Southport and Ormskirk Hospital NHS Trust, Southport, United Kingdom, ¹⁸Pomeranian Medical University in Szczecin, Szczecin, Poland, ¹⁹Instituto Mexicano del Seguro Social, Ciudad de México, Mexico, ²⁰Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²¹IMSS, Ciudad de México, Mexico, ²²Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy, ²³Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²⁴Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²⁵Walter and Eliza Hall Institute, Melbourne, Australia, ²⁶Mayo Clinic, Rochester, MN, Rochester, MN, ²⁷North Bristol NHS Trust, Bristol, United Kingdom, ²⁸Rayne Institute, University College London, London, United Kingdom, ²⁹Centro Medico Pensiones, Merida, Mexico, ³⁰Hospital Angeles Villahermosa, Ciudad de México, Mexico, ³¹Centro de Est. de Inv. Bas. y Clinica, S.C., Guadalajara, Mexico, ³²Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ³³Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom, ³⁴Leiden University Medical Center & King's College London, London, United Kingdom, ³⁵CoVAD study group, Wolwehampton, United Kingdom
Background/Purpose: COVID-19 vaccination in autoimmune diseases (COVAD) study is a large-scale real-world data on COVID-19 vaccine safety in autoimmune rheumatic diseases (AIRDs) including rheumatoid arthritis…
Abstract Number: 1292 • ACR Convergence 2022
Telemedicine’s Impact on Radiologic Ordering in an Academic Rheumatology Practice During the COVID-19 Pandemic
Ben Kellogg, Robert French, Emily Vinson, Erin McCrum and david leverenz, Duke University School of Medicine, Durham, NC
Background/Purpose: The COVID-19 pandemic necessitated the rapid implementation of telemedicine, and this shift's impact on practice patterns is still being characterized. We theorized that telemedicine…
Abstract Number: 1760 • ACR Convergence 2022
Diagnoses Rates in Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus Patients During COVID-19
W. Cliff Rutter, Will Cavers, Jean Park, Elisea Avalos-Reyes and Kjel Johnson, CVS Health, Lincoln, RI
Background/Purpose: COVID-19 is of particular concern to patients with autoimmune rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].